Patient-reported common symptoms as an assessment of interventions in medication reviews

• Verfasst von: Schoenmakers, Tim [VerfasserIn]
• Verfasst von: Wensing, Michel [VerfasserIn]
• Titel: Patient-reported common symptoms as an assessment of interventions in medication reviews
• Titelzusatz: a randomised, controlled trial
• Verf.angabe: Tim W.A. Schoenmakers, Michel Wensing, Peter A.G.M. De Smet, Martina Teichert
• Jahr: 2018
• Jahr des Originals: 2017
• Umfang: 9 S.
• Fussnoten: Published online: 5 December 2017 ; Gesehen am 12.07.2018
• Titel Quelle: Enthalten in: International journal of clinical pharmacy
• Ort Quelle: Dordrecht [u.a.] : Springer, 2011
• Jahr Quelle: 2018
• Band/Heft Quelle: 40(2018), 1, Seite 126-134
• ISSN Quelle: 2210-7711
• DOI: doi:10.1007/s11096-017-0575-7
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1577533267

Abstract

Background: A ‘Patient-Reported Outcome Measure, Inquiry into Side Effects’ (PROMISE) instrument was developed for patients to report common symptoms in clinical medication reviews. Objective To determine changes in patient-reported drug-associated symptoms collected by PROMISE before and after community pharmacist-led clinical medication reviews compared with usual care. Setting Community pharmacies in the Netherlands. Methods: Patients were randomised into an intervention group (IG) and a control group (CG). PROMISE was used to collect symptoms experienced during the previous month, and any suspected drug-associated symptoms from both groups at baseline and at follow-up after 3 months. IG patients received a one-time clinical medication review, while CG patients received usual care. Main outcome measure: Mean number of drug-associated symptoms at follow-up. Results Measurements were completed by 78 IG and 67 CG patients from 15 community pharmacies. Mean numbers of drug-associated symptoms per patient at follow-up were 4.0 in the IG and 5.0 in the CG, with an incident rate ratio between the groups of 0.90 (95% CI 0.62-1.33). Mean numbers of drug-associated symptoms per patient reported at follow-up and persisting since baseline were 2.1 in the IG and 2.6 in the CG, with an incident rate ratio of 0.85 (95% CI 0.43-1.42). The lowest percentages of persisting drug-associated symptoms detected in the IG were ‘palpitations’ and ‘stomach pain, dyspepsia’ while in the CG they were ‘stomach pain, dyspepsia’ and ‘trembling, shivering’. Conclusion: PROMISE provided meaningful information on drug-associated symptoms in clinical medication reviews, however the number of drug-associated symptoms was not reduced by performing clinical medication reviews compared with usual care.